3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia
33
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Lymphoma
24
Burkitt Lymphoma
14
Leukemia, Biphenotypic, Acute
10
Urinary Bladder Neoplasms
7
Breast Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
6
Leukemia, Myeloid, Acute
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Myelodysplastic Syndromes
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Mantle-Cell
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Dendritic Cell Sarcoma, Interdigitating
4
Urethral Neoplasms
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Osteosarcoma
3
Lymphoma, Large-Cell, Anaplastic
3
Lymphoma, Follicular
3
Leukemia, Myelomonocytic, Chronic
3
Anemia, Refractory, with Excess of Blasts
3
Sarcoma
2
Myeloproliferative Disorders
2
Myelodysplastic-Myeloproliferative Diseases
2
Mycosis Fungoides
2
Medulloblastoma
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Promyelocytic, Acute
2
Interventions
Cyclophosphamide
2
palbociclib
1
olaparib
1
fludarabine
1
durvalumab
1
binimetinib
1
atezolizumab
1
Methotrexate
1
Cisplatin
1
Carboplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Triple Negative Breast Neoplasms
×
Methotrexate
×
Clear all
NCT00022516
2016-09-16
22-00
ETOP IBCSG Partners Foundation
Phase 3
Completed
1,086 enrolled
10 charts